Strategic Partnership Announcement
10x Genomics, Inc. (Nasdaq: TXG) announced that PharosAI, a UK research consortium, will use its Xenium spatial platform to create one of the world’s most comprehensive multimodal cancer datasets. Backed by £18.9 million from the UK Government’s Research Ventures Catalyst and additional support from charities and industry partners, PharosAI aims to accelerate earlier diagnosis, precision therapies, and new treatment discovery.
Transforming Cancer Research with AI
PharosAI unites King’s College London, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust, and Barts Health NHS Trust. By leveraging Xenium, the consortium will convert decades of archived NHS cancer samples into high-resolution datasets that integrate genomic, transcriptomic, imaging, and spatial biology data. These datasets will be paired with advanced AI models to uncover hidden biological patterns and drive breakthroughs in diagnosis and drug discovery.
Leadership Perspective
Professor Anita Grigoriadis, CEO of PharosAI, emphasized that fragmented data has slowed AI’s impact in cancer care. She noted that PharosAI’s approach, combining rich datasets with cutting-edge AI tools, will enable earlier diagnoses and more targeted therapies. Serge Saxonov, CEO of 10x Genomics, highlighted Xenium’s ability to deliver consistent, high-quality spatial data at scale, providing the foundation for next-generation cancer research.
Focus on Breast, Lung, and Pancreatic Cancer
The initiative will begin with breast cancer before expanding to lung and pancreatic cancers. Thousands of clinical tissue samples will be included, with custom-designed gene panels developed in collaboration with 10x Genomics to align assays with the molecular features most relevant to each cancer type.
Building an Ecosystem for Breakthroughs
PharosAI will democratize access to its datasets, ensuring secure availability to researchers and innovators worldwide. Running through 2027, the program positions the UK at the forefront of AI-driven cancer research and builds a collaborative ecosystem for precision medicine.
Investment Perspective
For investors, this collaboration underscores 10x Genomics’ role as a critical enabler of AI-driven healthcare innovation. By powering one of the largest multimodal cancer datasets ever assembled, the company is reinforcing its leadership in spatial biology and expanding its relevance in oncology. The scale of PharosAI’s program highlights growing demand for advanced research platforms, suggesting long-term growth opportunities for 10x Genomics as precision medicine accelerates globally.
Conclusion
10x Genomics’ partnership with PharosAI demonstrates how advanced spatial biology technologies can unlock the full potential of AI in cancer research. With strong institutional backing and a clear roadmap, the initiative is poised to deliver breakthroughs that reshape patient care and outcomes.
About the Companies
10x Genomics, Inc. 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Its integrated solutions for single cell and spatial biology are behind breakthroughs in oncology, immunology, neuroscience, and more.
PharosAI Consortium PharosAI brings together King’s College London, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust, and Barts Health NHS Trust. Supported by charities and industry partners, the consortium is focused on creating AI-ready cancer datasets to drive earlier diagnosis, precision therapies, and new treatment discovery.
Forward-looking information is subject to risks and uncertainties. Please read our full Disclaimer.
